Clinicians' recognition of the metabolic adverse effects of antipsychotic medications

Peter F Buckley, Del D. Miller, Beth Singer, John Arena, Edna M. Stirewalt

Research output: Contribution to journalArticle

87 Scopus citations

Abstract

There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.

Original languageEnglish (US)
Pages (from-to)281-288
Number of pages8
JournalSchizophrenia Research
Volume79
Issue number2-3
DOIs
Publication statusPublished - Nov 15 2005

    Fingerprint

Keywords

  • Antipsychotics
  • Diabetes mellitus
  • Metabolic complications
  • Weight gain

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Buckley, P. F., Miller, D. D., Singer, B., Arena, J., & Stirewalt, E. M. (2005). Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophrenia Research, 79(2-3), 281-288. https://doi.org/10.1016/j.schres.2005.04.010